<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00520572</url>
  </required_header>
  <id_info>
    <org_study_id>D1520C00001</org_study_id>
    <nct_id>NCT00520572</nct_id>
  </id_info>
  <brief_title>A 6-month Randomised, Double-blind, Open Arm Comparator, Phase IIb, With AZD9056, in Patients With Rheumatoid Arthritis (RA)</brief_title>
  <official_title>A Randomised, Double-Blind (With Open Comparator Etanercept Limb), Placebo-Controlled, Phase IIb, Multicentre Study to Evaluate the Efficacy of 4 Doses of AZD9056 Administered for 6 Months on the Signs and Symptoms of Rheumatoid Arthritis in Patients With Active Disease Receiving Background Methotrexate or Sulphasalazine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to confirm that AZD9056 is effective in treating rheumatoid
      arthritis with regard to signs and symptoms and to determine what dose is favourable over a
      6-month treatment period. Patients will receive background treatment with either Methotrexate
      or Sulphasalazine
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>American College of Rheumatology 20 Response (ACR20) at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>The number of participants with greater to or equal to 20% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, disease activity and physical function; physician's assessment of disease activity; and CRP) after 6 months' treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 50 Response (ACR50) at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>The number of participants with greater to or equal to 50% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, disease activity and physical function; physician's assessment of disease activity; and CRP) after 6 months' treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 70 Response (ACR70) at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>The number of participants with greater to or equal to 70% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of pain, disease activity and physical function; physician's assessment of disease activity; and CRP) after 6 months' treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score (Based on 28 Joint Count) (DAS28) at 6 Months.</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change from baseline in the DAS28 composite score (a measure of RA symptoms including: joint swelling and tenderness; patient's assessment of disease activity; and ESR) after 6 months' treatment. A change of zero indicates no effect of treatment and a negative change of 1.2 indicates a clinically important improvement in symptoms. (The DAS scale runs from 0 to 10, with the higher scores indicating worse RA symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire - Disability Index (HAQ-DI) at 6 Months.</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change from baseline in HAQ-DI (a measure of patients assessment of physical function scored between zero and 3) after 6 months' treatment, calculated as score at 6 months minus score at baseline. A change of zero indicates no effect of treatment and a negative change of 0.22 or greater indicates an improvement in symptoms. (The HAQ-DI scale runs from 0 to 3, with higher scores indicating greater disability).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">385</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Etanercept 50mg, subcutaneous, once weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg oral, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg oral, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg oral, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400mg once, daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9056</intervention_name>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RA with active disease defined as: ≥4 swollen joints and ≥6
             tender/painful joints, and either have (blood tests) elevated erythrocyte
             sedimentation rate (ESR) or C-reactive protein (CRP). At least one of the following:
             documented history and current presence of positive rheumatoid factor (blood test),
             baseline radiographic erosion.

        Be receiving either oral (tablets) or subcutaneous/intramuscular (injection) methotrexate
        for at least 6 months prior to randomisation.

        Exclusion Criteria:

          -  Any other inflammatory disease in addition to RA that may interfere with the study
             (e.g. polymyalgia rheumatica, giant cell arteritis, reactive arthritis, e t c).
             Current chronic pain disorders including fibromyalgia and chronic fatigue syndromes.
             Persistently abnormal liver function enzymes (blood test).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Keystone, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mount Sinai Hospital, New York</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zoltan Koroknai, MD, D.E.A.A.</last_name>
    <role>Study Chair</role>
    <affiliation>Omnicare Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Olympia</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Planta Baja San Juan</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodsville</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victoria Park</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>George Town</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Johns</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cd. Juarez</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tapachula</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tijuana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elblag</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sopot</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj-napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ploiesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sf. Gheorghe</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sankt-peterburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bansky Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piestany</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Hungary</country>
    <country>Sweden</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2007</study_first_submitted>
  <study_first_submitted_qc>August 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2007</study_first_posted>
  <results_first_submitted>July 22, 2010</results_first_submitted>
  <results_first_submitted_qc>September 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 4, 2010</results_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant enrolled on 01 August 2007, the last participant completed the study on 08 April 2009. Participants were recruited from 59 centres in 12 countries in Australia, Canada, Europe, Russia, South America, and the USA.</recruitment_details>
      <pre_assignment_details>Male/female participants with active rheumatoid arthritis (and on background methotrexate or sulphasalazine) were randomly assigned to receive AZD9056 at 50, 100, 200 or 400 mg once daily, placebo or etanercept. It was planned to randomise approximately 360 participants, 60 to the open-label etanercept arm and 300 to the AZD9056 or placebo arms</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD9056 50 mg</title>
          <description>AZD9056 50 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="P2">
          <title>AZD9056 100 mg</title>
          <description>AZD9056 100 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="P3">
          <title>AZD9056 200 mg</title>
          <description>AZD9056 200 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="P4">
          <title>AZD9056 400 mg</title>
          <description>AZD9056 400 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo to AZD9056, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="P6">
          <title>Etanercept</title>
          <description>Etanercept 50 mg, subcutaneous injection, once weekly, open label</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64">Participants randomised. One of these participants did not subsequently receive treatment.</participants>
                <participants group_id="P2" count="64">Participants randomised.</participants>
                <participants group_id="P3" count="64">Participants randomised. One of these participants did not subsequently receive treatment.</participants>
                <participants group_id="P4" count="64">Participants randomised.</participants>
                <participants group_id="P5" count="65">Participants randomised.</participants>
                <participants group_id="P6" count="64">Participants randomised.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52">Participants completed the study.</participants>
                <participants group_id="P2" count="50">Participants completed the study.</participants>
                <participants group_id="P3" count="49">Participants completed the study.</participants>
                <participants group_id="P4" count="50">Participants completed the study.</participants>
                <participants group_id="P5" count="53">Participants completed the study.</participants>
                <participants group_id="P6" count="62">Participants completed the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incorrect enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Oral corticotherapy for acute urticaria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Long break in taking Medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive Treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD9056 50 mg</title>
          <description>AZD9056 50 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="B2">
          <title>AZD9056 100 mg</title>
          <description>AZD9056 100 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="B3">
          <title>AZD9056 200 mg</title>
          <description>AZD9056 200 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="B4">
          <title>AZD9056 400 mg</title>
          <description>AZD9056 400 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo to AZD9056, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="B6">
          <title>Etanercept</title>
          <description>Etanercept 50 mg, subcutaneous injection, once weekly, open label</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="63"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="63"/>
            <count group_id="B4" value="64"/>
            <count group_id="B5" value="65"/>
            <count group_id="B6" value="64"/>
            <count group_id="B7" value="383"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="12.8"/>
                    <measurement group_id="B2" value="54" spread="11.5"/>
                    <measurement group_id="B3" value="50" spread="11.9"/>
                    <measurement group_id="B4" value="52" spread="11.8"/>
                    <measurement group_id="B5" value="51" spread="11.9"/>
                    <measurement group_id="B6" value="51" spread="10.8"/>
                    <measurement group_id="B7" value="51.7" spread="11.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="59"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="55"/>
                    <measurement group_id="B7" value="329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>American College of Rheumatology 20 Response (ACR20) at 6 Months</title>
        <description>The number of participants with greater to or equal to 20% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient’s assessment of pain, disease activity and physical function; physician’s assessment of disease activity; and CRP) after 6 months’ treatment</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9056 50 mg</title>
            <description>AZD9056 50 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O2">
            <title>AZD9056 100 mg</title>
            <description>AZD9056 100 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O3">
            <title>AZD9056 200 mg</title>
            <description>AZD9056 200 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O4">
            <title>AZD9056 400 mg</title>
            <description>AZD9056 400 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo to AZD9056, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O6">
            <title>Etanercept</title>
            <description>Etanercept 50 mg, subcutaneous injection, once weekly, open label</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 20 Response (ACR20) at 6 Months</title>
          <description>The number of participants with greater to or equal to 20% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient’s assessment of pain, disease activity and physical function; physician’s assessment of disease activity; and CRP) after 6 months’ treatment</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 50 Response (ACR50) at 6 Months</title>
        <description>The number of participants with greater to or equal to 50% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient’s assessment of pain, disease activity and physical function; physician’s assessment of disease activity; and CRP) after 6 months’ treatment.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9056 50 mg</title>
            <description>AZD9056 50 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O2">
            <title>AZD9056 100 mg</title>
            <description>AZD9056 100 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O3">
            <title>AZD9056 200 mg</title>
            <description>AZD9056 200 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O4">
            <title>AZD9056 400 mg</title>
            <description>AZD9056 400 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo to AZD9056, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O6">
            <title>Etanercept</title>
            <description>Etanercept 50 mg, subcutaneous injection, once weekly, open label</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 50 Response (ACR50) at 6 Months</title>
          <description>The number of participants with greater to or equal to 50% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient’s assessment of pain, disease activity and physical function; physician’s assessment of disease activity; and CRP) after 6 months’ treatment.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 70 Response (ACR70) at 6 Months</title>
        <description>The number of participants with greater to or equal to 70% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient’s assessment of pain, disease activity and physical function; physician’s assessment of disease activity; and CRP) after 6 months’ treatment</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9056 50 mg</title>
            <description>AZD9056 50 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O2">
            <title>AZD9056 100 mg</title>
            <description>AZD9056 100 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O3">
            <title>AZD9056 200 mg</title>
            <description>AZD9056 200 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O4">
            <title>AZD9056 400 mg</title>
            <description>AZD9056 400 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo to AZD9056, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O6">
            <title>Etanercept</title>
            <description>Etanercept 50 mg, subcutaneous injection, once weekly, open label</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 70 Response (ACR70) at 6 Months</title>
          <description>The number of participants with greater to or equal to 70% improvement in the ACR composite score (a measure of RA symptoms including: joint swelling and tenderness; patient’s assessment of pain, disease activity and physical function; physician’s assessment of disease activity; and CRP) after 6 months’ treatment</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score (Based on 28 Joint Count) (DAS28) at 6 Months.</title>
        <description>Change from baseline in the DAS28 composite score (a measure of RA symptoms including: joint swelling and tenderness; patient’s assessment of disease activity; and ESR) after 6 months’ treatment. A change of zero indicates no effect of treatment and a negative change of 1.2 indicates a clinically important improvement in symptoms. (The DAS scale runs from 0 to 10, with the higher scores indicating worse RA symptoms).</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9056 50 mg</title>
            <description>AZD9056 50 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O2">
            <title>AZD9056 100 mg</title>
            <description>AZD9056 100 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O3">
            <title>AZD9056 200 mg</title>
            <description>AZD9056 200 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O4">
            <title>AZD9056 400 mg</title>
            <description>AZD9056 400 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo to AZD9056, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O6">
            <title>Etanercept</title>
            <description>Etanercept 50 mg, subcutaneous injection, once weekly, open label</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score (Based on 28 Joint Count) (DAS28) at 6 Months.</title>
          <description>Change from baseline in the DAS28 composite score (a measure of RA symptoms including: joint swelling and tenderness; patient’s assessment of disease activity; and ESR) after 6 months’ treatment. A change of zero indicates no effect of treatment and a negative change of 1.2 indicates a clinically important improvement in symptoms. (The DAS scale runs from 0 to 10, with the higher scores indicating worse RA symptoms).</description>
          <units>Composite score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="1.27"/>
                    <measurement group_id="O2" value="-1.4" spread="1.63"/>
                    <measurement group_id="O3" value="-1.1" spread="1.47"/>
                    <measurement group_id="O4" value="-1.4" spread="1.37"/>
                    <measurement group_id="O5" value="-1" spread="1.24"/>
                    <measurement group_id="O6" value="-2.3" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire - Disability Index (HAQ-DI) at 6 Months.</title>
        <description>Change from baseline in HAQ-DI (a measure of patients assessment of physical function scored between zero and 3) after 6 months’ treatment, calculated as score at 6 months minus score at baseline. A change of zero indicates no effect of treatment and a negative change of 0.22 or greater indicates an improvement in symptoms. (The HAQ-DI scale runs from 0 to 3, with higher scores indicating greater disability).</description>
        <time_frame>Baseline to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD9056 50 mg</title>
            <description>AZD9056 50 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O2">
            <title>AZD9056 100 mg</title>
            <description>AZD9056 100 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O3">
            <title>AZD9056 200 mg</title>
            <description>AZD9056 200 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O4">
            <title>AZD9056 400 mg</title>
            <description>AZD9056 400 mg, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo to AZD9056, oral tablets, once daily, double blinded</description>
          </group>
          <group group_id="O6">
            <title>Etanercept</title>
            <description>Etanercept 50 mg, subcutaneous injection, once weekly, open label</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire - Disability Index (HAQ-DI) at 6 Months.</title>
          <description>Change from baseline in HAQ-DI (a measure of patients assessment of physical function scored between zero and 3) after 6 months’ treatment, calculated as score at 6 months minus score at baseline. A change of zero indicates no effect of treatment and a negative change of 0.22 or greater indicates an improvement in symptoms. (The HAQ-DI scale runs from 0 to 3, with higher scores indicating greater disability).</description>
          <units>Composite score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="65"/>
                <count group_id="O6" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.57"/>
                    <measurement group_id="O2" value="-0.3" spread="0.51"/>
                    <measurement group_id="O3" value="-0.2" spread="0.5"/>
                    <measurement group_id="O4" value="-0.3" spread="0.55"/>
                    <measurement group_id="O5" value="-0.3" spread="0.46"/>
                    <measurement group_id="O6" value="-0.6" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD9056 50 mg</title>
          <description>AZD9056 50 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="E2">
          <title>AZD9056 100 mg</title>
          <description>AZD9056 100 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="E3">
          <title>AZD9056 200 mg</title>
          <description>AZD9056 200 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="E4">
          <title>AZD9056 400 mg</title>
          <description>AZD9056 400 mg, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo to AZD9056, oral tablets, once daily, double blinded</description>
        </group>
        <group group_id="E6">
          <title>Etanercept</title>
          <description>Etanercept 50 mg, subcutaneous injection, once weekly, open label</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Ureteral Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid Atheritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Hybrid ACR, ACRn, individual ACR components, Erythrocyte sedimentation rate, Short-form-36, Rheumatoid Arthritis Quality of Life, Patient Assessment of Fatigue and DEXA X-ray scanning did not provide extra information so are not presented</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

